Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors

Annals of Oncology

Volumn 21, Issue 3, 2009, Pages 633-639

  Schmid, P ^a   Kiewe, P ^b   Possinger, K ^b   Korfel, A ^b   Lindemann, S ^c   Giurescu, M ^c   Reif, S ^c   Wiesinger, H ^c   Thiel, E ^b   Kuhnhardt D ^b  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Chemotherapy; Epothilones; First in human study; Microtubule stabilizing agent; Phase I study; Solid tumors

Indexed keywords

SAGOPILONE;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ATAXIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPONATREMIA; LEUKOPENIA; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MYALGIA; MYOCLONUS; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; SALVAGE THERAPY; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 77649156159     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp491     Document Type: Article

References (26)

1. Horwitz SB, Cohen D, Rao S et al. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993; 15: 55-61.
2. ten Tije AJ, Verweij J, Loos WJ et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42: 665-685.
3. Gerth K, Bedorf N, Höfle G et al. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996; 49: 560-563.
4. ®). J Biol Chem 1997; 272: 2534-2541.
5. Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55: 2325-2333.
6. Lee FYF, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7: 1429-1437.
7. Klar U, Buchmann B, Schwede W et al. Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 2006; 45: 7942-7948.
8. Mielke S, Mross K, Glocker F-X et al. Neurotoxicity of paclitaxel infused weekly over one versus three hours: preliminary results of a phase III trial. Proc Am Soc Clin Oncol 2001; 20: (Abstr 425).
9. Roché HH, Cure H, Bunnell C et al. A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic breast cancer (MBC) previously treated with an anthracycline. Proc Am Soc Clin Oncol 2003; 22: (Abstr 69).
10. Roché H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25: 3415-3420.
11. Marupudi NI, Han JE, Li KW et al. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007; 6: 609-621.
12. Abraham J, Agrawal M, Bakke S et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003; 21: 1866-1873.
13. Aghajanian C, Burris HA III, Jones S et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007; 25: 1082-1088.
14. Faivre S, Delbaldo C, Boige V et al. Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies. Eur J Cancer 2008; 44: 674-682.
15. Mani S, McDaid H, Hamilton A et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004; 10: 1289-1298.
16. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210-5217.
17. Vansteenkiste J, Lara PN Jr., Le Chevalier T et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007; 25: 3448-3455.
18. Beer TM, Higano CS, Saleh M et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 2007; 25: 565-570.
19. Okuno S, Maples WJ, Mahoney MR et al. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium. J Clin Oncol 2005; 23: 3069-3073.
20. Rubin EH, Rothermel J, Tesfaye F et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005; 23: 9120-9129.
21. Zhuang SH, Agrawal M, Edgerly M et al. A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005; 103: 1932-1938.
22. Gatzemeier U, von Pawel J, Eschbach C et al. Phase II trial of the novel epothilone sagopilone (ZK-EPO) as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer. In Presented at the ECCO 14. Barcelona, Spain, 23-27 September 2007.
23. Rustin G, Reed N, Jayson G et al. Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. In Presented at the 15th International Meeting of the European Society for Gynaecological Oncology. Berlin, Germany, 28 October to 1 November 2007.
24. Graff J, Smith DC, Neerukonda L et al. Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer. In Presented at the 44th ASCO Annual Meeting. Chicago, IL, 30 May to 3 June 2008.
25. Wenk D, DeConti RC, Urbas P et al. Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with metastatic melanoma. J Clin Oncol 2008; 26: (Abstr 9046).
26. Gauler TC, Christoph D, Gamarra F et al. Phase I study of sagopilone (ZK-EPO) in combination with cisplatin in patients with chemotherapy-naïve extensive-disease small-cell lung cancer (ED-SCLC). Ann Oncol 2008; 19 (Suppl 8): (Abstr 331P).